Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for clues to rare immune disease

NCT ID NCT00315380

Knowledge-focused Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This study follows 700 people with eosinophilic granulomatosis with polyangiitis (EGPA), a rare immune disorder causing asthma, high eosinophil levels, and blood vessel inflammation. Researchers aim to discover biological markers that can measure disease activity and predict treatment response. No new treatments are tested; the goal is to better understand and monitor the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 700 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Apr 2006

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Individuals with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Enrollment will be sequential and participants will have disease in various stages and of different duration.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients with a diagnosis of eosinophilic granulomatosis with polyangiitis are eligible for the study. Parent or guardian willing to provide informed consent, if applicable Exclusion Criteria: \- Inability to give informed consent and to sign the consent form

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Churg-Strauss syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

eosinophilic granulomatosis with polyangiitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Churg-Strauss syndrome Eosinophilic granulomatosis with polyangiitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AOU Meyer IRCCS

    RECRUITING

    Florence, Italy

  • Brigham and Women's Hospital

    COMPLETED

    Boston, Massachusetts, 02215, United States

  • Cambridge University Hospitals Nhs Foundation Trust

    RECRUITING

    Cambridge, United Kingdom

  • Cleveland Clinic Foundation

    COMPLETED

    Cleveland, Ohio, 44195, United States

  • Guy'S and St Thomas' Nhs Foundation Trust

    RECRUITING

    London, United Kingdom

  • Imperial College Healthcare NHS Trust/ Imperial College London

    RECRUITING

    London, W12 0NN, United Kingdom

  • Mayo Clinic

    COMPLETED

    Rochester, Minnesota, 55905, United States

  • Mount Sinai Hospital

    COMPLETED

    Toronto, Ontario, Canada

  • National Jewish Health

    COMPLETED

    Denver, Colorado, 80206, United States

  • St. Joseph's Healthcare

    RECRUITING

    Hamilton, Ontario, Canada

  • University of California San Diego

    COMPLETED

    San Diego, California, 92122, United States

  • University of Pennsylvania

    COMPLETED

    Philadelphia, Pennsylvania, 19104, United States

  • University of Pittsburgh

    COMPLETED

    Pittsburgh, Pennsylvania, 15260, United States

  • University of Utah

    COMPLETED

    Salt Lake City, Utah, 84112, United States

  • medius KLINIK KIRCHHEIM

    RECRUITING

    Kirchheim unter Teck, 73230, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.